Walvax Biotechnology Co., Ltd.

SZSE:300142 Rapporto sulle azioni

Cap. di mercato: CN¥23.2b

Walvax Biotechnology Performance dei guadagni passati

Il passato criteri di controllo 0/6

Walvax Biotechnology's earnings have been declining at an average annual rate of -10.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 19.3% per year. Walvax Biotechnology's return on equity is 1.4%, and it has net margins of 4%.

Informazioni chiave

-10.6%

Tasso di crescita degli utili

-11.6%

Tasso di crescita dell'EPS

Biotechs Crescita del settore11.3%
Tasso di crescita dei ricavi19.3%
Rendimento del capitale proprio1.4%
Margine netto4.0%
Ultimo aggiornamento sui guadagni30 Sep 2024

Aggiornamenti sulle prestazioni recenti

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Apr 07
There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Recent updates

Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Sep 24
Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Jun 19
Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

May 23
Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Apr 07
There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 02
Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Mar 01
Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Ripartizione dei ricavi e delle spese

Come Walvax Biotechnology guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

SZSE:300142 Ricavi, spese e utili (CNY Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 243,0971221,337621
30 Jun 243,3791351,597687
31 Mar 243,8802621,787672
31 Dec 234,1144191,868763
30 Sep 234,5387512,025818
30 Jun 234,9067632,206885
31 Mar 235,2648622,353962
01 Jan 235,0867292,301922
30 Sep 225,0405952,320958
30 Jun 224,4615302,011827
31 Mar 223,6854341,729704
01 Jan 223,4634281,631616
30 Sep 213,5019321,575355
30 Jun 213,7151,2611,670311
31 Mar 213,2601,0531,473212
31 Dec 202,9391,0031,345174
30 Sep 201,8904571,000174
30 Jun 201,19411969982
31 Mar 201,0578568562
31 Dec 191,12114266063
30 Sep 191,0981,44455775
30 Jun 191,0001,42654195
31 Mar 199331,430412135
31 Dec 188741,415418138
30 Sep 18807-407504127
30 Jun 18786-421399166
31 Mar 18700-484432111
31 Dec 17668-53743994
30 Sep 1762826527672
30 Jun 175551893450
31 Mar 17466833580
31 Dec 16591703750
30 Sep 16692-9636410
30 Jun 16885-9366590
31 Mar 161,045-8356220
31 Dec 151,006-8416240
30 Sep 158431825270
30 Jun 157311385570
31 Mar 157051475500
31 Dec 147191435540
30 Sep 14816-1394690
30 Jun 14750-914330
31 Mar 14676-293910
31 Dec 13583483550

Guadagni di qualità: 300142 has a large one-off loss of CN¥120.5M impacting its last 12 months of financial results to 30th September, 2024.

Margine di profitto in crescita: 300142's current net profit margins (4%) are lower than last year (16.5%).


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: 300142's earnings have declined by 10.6% per year over the past 5 years.

Accelerare la crescita: 300142's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Guadagni vs Settore: 300142 had negative earnings growth (-83.7%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).


Rendimento del capitale proprio

ROE elevato: 300142's Return on Equity (1.4%) is considered low.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate